Trial · NCT02075255
Outcomes34
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 34
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control | Week 28 | Full analysis set | Percent | MEDIAN |
| SECONDARY | Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control | Week 28 | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL | Week 28 | Full analysis set, baseline blood eosinophil \>=300/uL | Percent | MEDIAN |
| SECONDARY | The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control | Week 28 | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control | Week 28 | Full analysis set, eligible for 100% reduction (ie, patients with baseline OCS dose \<= 12.5 mg) | Participants | NUMBER |
| SECONDARY | The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control. | Week 28 | Full analysis set | Participants | NUMBER |
| SECONDARY | The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control | Week 28 | Full analysis set | Participants | NUMBER |
| SECONDARY | Number and Percentage of Patients With ≥1 Asthma Exacerbation | Immediately following the randomisation through Study Week 28 | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to the First Asthma Exacerbation | The time from randomisation to the date of first asthma exacerbation over 28 weeks | Full analysis set | Days | MEDIAN |
| SECONDARY | Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit | The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks. | Full analysis set | Days | MEDIAN |
| SECONDARY | The Annualized Rate of Asthma Exacerbation | The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up | Full analysis set | events/year | LEAST_SQUARES_MEAN |
| SECONDARY | The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization | The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up | Full analysis set | events/year | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Days in Hospital Due to Asthma | The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up | Full analysis set | Days | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Pre-bronchodilator FEV1 | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | Liter | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Asthma Symptom Scores (Total) | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime) | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime) | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Rescue Medication Use | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | number of puffs per day | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow) | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | Liter/min | MEAN |
| SECONDARY | Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow) | Change from baseline at week 28 | Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28. | Liter/min | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02075255/outcomes